Weiss Multi Strategy Advisers LLC Zymeworks Inc. Transaction History

Weiss Multi Strategy Advisers LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$6.0 - $16.98 $104,316 - $295,214	-17,386 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$15.19 - $29.33 $1,078 - $2,082	-71 Reduced 0.41%	17,386 $285,000
Q3 2021 Nov 15, 2021	BUY	$27.35 - $37.28 $10,393 - $14,166	380 Added 2.23%	17,457 $507,000
Q2 2021 Aug 16, 2021	BUY	$26.5 - $38.23 $16,218 - $23,396	612 Added 3.72%	17,077 $592,000
Q1 2021 May 14, 2021	SELL	$29.83 - $56.81 $108,282 - $206,220	-3,630 Reduced 18.06%	16,465 $520,000
Q4 2020 Feb 16, 2021	SELL	$39.12 - $54.99 $9,036 - $12,702	-231 Reduced 1.14%	20,095 $950,000
Q3 2020 Nov 16, 2020	BUY	$29.21 - $46.58 $6,630 - $10,573	227 Added 1.13%	20,326 $947,000
Q2 2020 Aug 14, 2020	BUY	$33.67 - $40.0 $28,215 - $33,520	838 Added 4.35%	20,099 $725,000
Q1 2020 May 15, 2020	BUY	$24.28 - $49.8 $467,657 - $959,197	19,261 New	19,261 $683,000

296K

Ticker ZYME
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,694,400
Market Cap $906M
Description
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas...

Get notified when there are updates to the investment portfolio of Weiss Multi Strategy Advisers LLC, based on Form 13F filings with the SEC.

Stay updated on Weiss Multi Strategy Advisers LLC with notifications on news.